Showing 1 - 13 results of 13 for search 'Lhassane Ismaili', query time: 0.05s
Refine Results
-
1
Editorial: Advances in drug discovery for anti-Alzheimer’s agents by Lhassane Ismaili
Published 2022-09-01
Article -
2
-
3
-
4
Triazolopyridopyrimidine: A New Scaffold for Dual-Target Small Molecules for Alzheimer’s Disease Therapy by Lazhar Zribi, Irene Pachòn-Angona, Òscar M. Bautista-Aguilera, Daniel Diez-Iriepa, José Marco-Contelles, Lhassane Ismaili, Isabel Iriepa, Fakher Chabchoub
Published 2020-07-01
Article -
5
Efficient Two-Step Synthesis of Novel Pyrimido[4,5-<i>d</i>] Pyrimidines with Potent Neuroprotective, Antioxidant, and A<i>β</i> Anti-Aggregation Properties by Ghada Ben Ameur, Emna Maalej, Helene Martin, Anne-Sophie Jacquinot, Nadine Barbanneau, Paul J. Bernard, José Marco-Contelles, Fakher Chabchoub, Lhassane Ismaili
Published 2024-08-01
Article -
6
Imidazopyranotacrines as Non-Hepatotoxic, Selective Acetylcholinesterase Inhibitors, and Antioxidant Agents for Alzheimer′s Disease Therapy by Houssem Boulebd, Lhassane Ismaili, Manuela Bartolini, Abdelmalek Bouraiou, Vincenza Andrisano, Helene Martin, Alexandre Bonet, Ignacio Moraleda, Isabel Iriepa, Mourad Chioua, Ali Belfaitah, José Marco-Contelles
Published 2016-03-01
Article -
7
Design, Synthesis and Biological Evaluation of New Antioxidant and Neuroprotective Multitarget Directed Ligands Able to Block Calcium Channels by Irene Pachòn Angona, Solene Daniel, Helene Martin, Alexandre Bonet, Artur Wnorowski, Maciej Maj, Krzysztof Jóźwiak, Tiago Barros Silva, Bernard Refouvelet, Fernanda Borges, José Marco-Contelles, Lhassane Ismaili
Published 2020-03-01
Article -
8
Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca<sup>2+</sup> Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activati... by Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J. Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak, Lhassane Ismaili
Published 2022-12-01
Article -
9
Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy by Irene Pachón-Angona, Bernard Refouvelet, Rudolf Andrýs, Helène Martin, Vincent Luzet, Isabel Iriepa, Ignacio Moraleda, Daniel Diez-Iriepa, María-Jesús Oset-Gasque, José Marco-Contelles, Kamil Musilek, Lhassane Ismaili
Published 2019-01-01
Article -
10
Design and Synthesis of Multi-Functional Ligands through Hantzsch Reaction: Targeting Ca<sup>2+</sup> Channels, Activating Nrf2 and Possessing Cathepsin S Inhibitory, and Antioxida... by Irene Pachón-Angona, Paul J. Bernard, Alexey Simakov, Maciej Maj, Krzysztof Jozwiak, Anna Novotna, Carina Lemke, Michael Gütschow, Helene Martin, María-Jesús Oset-Gasque, José-Marco Contelles, Lhassane Ismaili
Published 2024-01-01
Article -
11
Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer’s disease therapy by Youssef Dgachi, Hélène Martin, Rim Malek, Daniel Jun, Jana Janockova, Vendula Sepsova, Ondrej Soukup, Isabel Iriepa, Ignacio Moraleda, Emna Maalej, M. Carmo Carreiras, Bernard Refouvelet, Fakher Chabchoub, José Marco-Contelles, Lhassane Ismaili
Published 2019-01-01
Article -
12
Synthesis and Biological Evaluation of Benzochromenopyrimidinones as Cholinesterase Inhibitors and Potent Antioxidant, Non-Hepatotoxic Agents for Alzheimer’s Disease by Youssef Dgachi, Oscar M. Bautista-Aguilera, Mohamed Benchekroun, Hélène Martin, Alexandre Bonet, Damijan Knez, Justyna Godyń, Barbara Malawska, Stanislav Gobec, Mourad Chioua, Jana Janockova, Ondrej Soukup, Fakher Chabchoub, José Marco-Contelles, Lhassane Ismaili
Published 2016-05-01
Article -
13
Chromenones as Multineurotargeting Inhibitors of Human Enzymes by Carina Lemke, Joscha Christmann, Jiafei Yin, José M. Alonso, Estefanía Serrano, Mourad Chioua, Lhassane Ismaili, María Angeles Martínez-Grau, Christopher D. Beadle, Tatiana Vetman, Florian M. Dato, Ulrike Bartz, Paul W. Elsinghorst, Markus Pietsch, Christa E. Müller, Isabel Iriepa, Timo Wille, José Marco-Contelles, Michael Gütschow
Published 2019-12-01
Article